UNSPSC 51352427: Estradiol/norgestimate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS900. This VA Drug Class (HS900) classifies this compound as belonging to the group HORMONES/SYNTHETICS/MODIFIERS, OTHER.

UNSPSC 51352427 Estradiol/norgestimate is a Commodity code covering a specific combination oral contraceptive pharmaceutical product. State and local governments procure this medication primarily through cooperative purchasing alliances and pharmacy benefit programs to supply health plans, employee group coverage, and public health clinics. Issuing bodies include state health and human services departments, multistate cooperative purchasing organizations, and state departments of administration that coordinate pharmaceutical procurement for covered populations. The work involves manufacturers and authorized pharmaceutical wholesalers negotiating supply agreements, pricing structures, and distribution terms with state and local government pharmacy benefit administrators.

Minnesota's Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with awarded vendors effective July 1, 2026. The Texas Health and Human Services Commission posted a Request for Information in April 2026 to gather vendor capabilities for implementing a Direct-to-Manufacturer Prescriptions program, exploring alternative distribution channels for pharmaceutical products outside traditional pharmacy benefit manager and wholesaler arrangements. MMCAP's RFP required vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson—with pricing weighted at 75 percent of evaluation and compliance with Good Manufacturing Practices and Drug Supply Chain Security Act certification mandatory. Recent activity concentrates in the Upper Midwest and Texas, with multistate cooperative vehicles and state health departments driving procurement strategy.